People
F2G names new chairman
9 April 2019 -

F2G Ltd, a European biotech company developing novel therapies for life-threatening fungal infections, announced yesterday that it has named Dr Patrick Vink as its new chairman of the board of directors with immediate effect.

Dr Vink replaces Dr Richard J White who stood down in December 2018.

Dr Vink has more than 30 years of experience in the biotechnology and pharmaceutical industry. He was earlier chief operating officer at Cubist Pharmaceuticals Inc. Prior to Cubist, he was head of the Global Hospital Business at Mylan Inc as part of the global executive team. Before this, he was head of Global Biopharmaceuticals at Sandoz (division of Novartis) and held senior positions at Biogen Inc Sanofi-Synthelabo, and Numico. Presently, he is on the board of several US and European publicly listed and private companies, including chairman of Acacia Pharma, Targovax and NMD Pharma and non-executive director of Spero Therapeutics, Arch Biopartners and Santhera AG.

Login
Username:

Password: